BPC-157 Legal Guide Blog
Regulatory updates, enforcement actions and legal analysis for BPC-157 and related peptides. Primary sources and plain-language explanations.
BPC-157 Regulation Timeline: Key Dates and Decisions
Chronological timeline of BPC-157 regulatory decisions. FDA actions, WADA listings, warning letters and compounding committee votes by date.
FDA Warning Letters to Peptide Sellers: What They Say
FDA warning letters sent to companies selling BPC-157 and other peptides. Violations cited, company responses and what the letters mean for the market.
Is BPC-157 Banned by the NCAA? Rules for College Athletes
BPC-157 and NCAA drug testing rules. Which banned substance categories apply, testing protocols and what a positive result means for college athletes.
BPC-157 and Compounding Pharmacies: FDA Rules Explained
FDA rules on compounding BPC-157 through 503A and 503B pharmacies. Advisory committee votes, bulk drug substance status and what prescribers need to know.
BPC-157 in Australia: TGA Rules and Legal Status
BPC-157 legal status in Australia. TGA classification, Schedule 4 requirements, import rules and what Australian buyers need to know.
Latest Posts
BPC-157 legal news, regulatory updates and enforcement actions tracked from primary sources. Every article on this blog cites the agencies that write the rules, not secondhand reports.
What You Will Find Here
This blog covers FDA warning letters, WADA rule changes, compounding pharmacy votes, import alert updates and court actions. Posts are organized by date and tagged by topic so you can find what matters to your situation. We add new articles when a regulatory event happens and update existing posts when the facts change.
How We Source Our Posts
Each post links to the original regulatory document. FDA warning letters link to the FDA enforcement database. WADA changes link to the Prohibited List announcements. TGA scheduling decisions link to legislation.gov.au. If a source is no longer accessible, we note it and explain what the document said.
Recent Coverage
In 2026, the FDA issued five warning letters to peptide sellers, the Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157 for the 503A bulks list, and the agency revised Import Alert 66-41. Australia completed its first full year with BPC-157 classified as Schedule 4. USADA and the DoD published updated guidance on prohibited peptides. Each of these events is covered in a dedicated post below.